Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to Expand its KRAS Cancer Program

Shots:

• Lupin to receive $20M up front, ~$700M as clinical, regulatory & commercial milestones with royalties on sales of the product. Boehringer Ingelheim to get right to utilize Lupin’s LNP3794 in combination with its KRAS inhibitors for patients with gastrointestinal and lung cancers harboring KRAS mutations
• The focus of the agreement is to robust Boehringer’s KRAS program and strengthen its portfolio for patients with gastrointestinal and lung cancer by licensing Lupin’s clinical-stage MEK inhibitor therapy
• Lupin’s LNP3794 is a MEK inhibitor, being developed for multiple cancer indications i.e, skin cancer, pancreatic cancer, NSCLC, colorectal cancer, or thyroid cancer. The preclinical data of BI’s KRAS inhibitor demonstrated an increased anti-tumor activity based on its complementary MOA in combination with MEK inhibitor

Click here to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Egypt Today